Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a saffron-derived compound boost radiation for sarcoma?

NCT ID NCT06476704

Disease control Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding a drug called liposomal transcrocetin (L-TC) to short-course radiation before surgery can kill more cancer cells in people with soft-tissue sarcoma. About 42 adults with localized or locally advanced sarcoma will be randomly assigned to receive radiation alone or radiation plus L-TC. The main goal is to see if the combination leads to a higher rate of near-complete tumor destruction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal transcrocetin (L-TC)
What this could lead to
If it works, this could improve the chance of eliminating most cancer cells before surgery, potentially reducing recurrence risk.
What could go wrong
This is a small early-phase trial (42 people) testing a new combination. The drug may not improve outcomes and could cause side effects like infusion reactions or toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Localized or locally advanced soft tissue sarcoma of extremity proven by biopsy histological grade 2 and 3. * Pathological expert proof-reading in reference centers * HFRT and surgery planned (regardless the potential inclusion in this trial) as decided in a multidisciplinary tumor board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021) * R0 surgery is feasible, in reference centers * Pre-biopsy MRI available * Performance status of 0-2 and life expectancy of at least 6 months Exclusion Criteria: * Patient who cannot undergo MRI * Patients with localized or locally advanced soft tissue sarcoma of extremity proven by biopsy with histological grade 1 * Previous radiation in the area * Woman who is pregnant or breastfeeding * Soft tissue sarcoma developed in irradiated area. * Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans * Patient with metastatic disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized or locally advanced soft-tissue sarcoma of the extremity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypoxia sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CGFL

    Dijon, France

  • ICANS

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.